Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Online health records, medical devices face IT security risks

Meanwhile, iWatch News reports on how the health information sector seems especially fond of lobbying's "revolving door."

22 Aug 2011

New source for sexual problems in men – buddies!

Social researchers have found that there may be a new source for sexual problems among middle-aged and older men and it could be the relationships between their female partners and the men's closest friends.

12 Aug 2011

Researchers identify new source for sexual problems in middle-aged, older men

Researchers have found a potential new source for sexual problems among middle-aged and older men: the relationships between their female partners and the men's closest friends.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

Even minor weight loss can improve men’s sex lives: Study

The team of Australian researchers placed 31 obese men with type 2 diabetes on either a meal replacement-based low-calorie diet or a low-fat, high-protein, reduced-carbohydrate diet meant to decrease calorie intake by 600 calories a day. A modest weight loss of 5 percent led to an easing of erectile dysfunction and improved sexual desire within eight weeks, and these improvements continued for 12 months, according to the study published Aug. 5 in The Journal of Sexual Medicine. Problems with urinary tract function also improved, the team added.

8 Aug 2011

Positive results from Antares Pharma VIBEX MTX clinical study on RA

Antares Pharma, Inc. today announced the positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate (MTX) for the treatment of rheumatoid arthritis.

5 Aug 2011

BioSante closes underwritten public offering of common stock

BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.

3 Aug 2011

Dangers of colon cleansing: More harm than good

According to a new study released today in the Journal of Family Practice colon cleaning may be harmful. Researchers from Georgetown University Medical School looked at 20 studies published in the last decade and found little evidence of benefit to colon cleansing. But they did find dozens of cases of problems: cramping, bloating, vomiting, electrolyte imbalance, renal failure, and even death.

1 Aug 2011

BioSante second quarter net loss increases to $15.0 million

BioSante Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2011.

26 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Ventus Medical launches Provent Sleep Apnea Therapy in India

Ventus Medical is pleased to announce the Indian launch of its proprietary Provent Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea.

20 Jul 2011

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.

11 Jul 2011

Poor diet, alcohol, drugs and smoking linked to sex problems

A new study published in The Journal of Sexual Medicine reveals that several unhealthy lifestyle factors, such as weight problems, physical inactivity, high alcohol consumption, tobacco smoking, and hard drugs are associated with sexual dysfunctions in men. Additionally, an unhealthy lifestyle is more common in persons who are sexually inactive.

7 Jul 2011